AstraZeneca has been granted approval from India’s Central Drugs Standard Control Organisation (CDSCO) to import tremelimumab concentrate, a medication used for a certain type of liver tumour. The drug, marketed under the brand name Imjudo, works by activating the immune system’s T-cells to target and attack cancer cells.
Tremelimumab is being studied as a potential treatment for a range of tumour types, including lung and head and neck cancer. The approval adds to AstraZeneca’s strong portfolio of oncology drugs, which includes treatments for breast cancer, ovarian cancer, and non-small cell lung cancer.
“We are pleased to have received approval from the CDSCO to import Imjudo for the treatment of liver cancer in India,” said Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca. “Imjudo is a powerful immunotherapy that has the potential to help patients with liver cancer live longer and better lives.”
The approval of Imjudo in India is a significant development for patients with liver cancer. Liver cancer is the third most common cancer in the world, and it is the leading cause of cancer death in India. The disease is often diagnosed at a late stage, when it is difficult to treat.
Imjudo is a monoclonal antibody that works by blocking the CTLA-4 protein. CTLA-4 is a molecule that helps to suppress the immune system. By blocking CTLA-4, Imjudo helps to unleash the immune system’s full power against cancer cells.
Imjudo is administered as an infusion every four weeks. The most common side effects of Imjudo are fatigue, nausea, and vomiting.
The approval of Imjudo in India is a welcome development for patients with liver cancer. The drug offers a new and effective treatment option for a disease that is often fatal.